Coherus BioSciences, Inc.

NASDAQ:CHRS

1.3 (USD) • At close September 13, 2024
Bedrijfsnaam Coherus BioSciences, Inc.
Symbool CHRS
Munteenheid USD
Prijs 1.3
Beurswaarde 149,771,700
Dividendpercentage 0%
52-weken bereik 1.2 - 4.97
Industrie Biotechnology
Sector Healthcare
CEO Mr. Dennis M. Lanfear
Website https://www.coherus.com

An error occurred while fetching data.

Over Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops

Vergelijkbare Aandelen

Eagle Pharmaceuticals, Inc. logo

Eagle Pharmaceuticals, Inc.

EGRX

4.31 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

1.51 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

3.09 USD

Quanterix Corporation logo

Quanterix Corporation

QTRX

12.82 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

11.33 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

2.37 USD

Pharvaris N.V. logo

Pharvaris N.V.

PHVS

20.92 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)